Our Goals

To align the incentives of all stakeholders involved in the patients’ healthcare journey related to sustainable strategies to improve medication adherence and persistence in patients with Type 2 diabetes.

Assess how improving medication adherence/ persistence improves critical clinical surrogates (HbA1c, renal function, lipids, blood pressure, weight).

Close the gap between clinical trial findings and real-world patient care.

Establish real world evidence related to drivers of medication adherence and related solutions to improve health and economic outcomes.

An Integrated Approach to Real World Evidence

About P-MAPP

Established under a Research Collaboration Agreement with the U.S. Food and Drug Administration (FDA), the P-MAPP links comprehensive longitudinal patient-centric data, acquired in the "voice of the patient" via customized surveys, with information contained in patient health records, pharmacy fill/refill information and medical claims to create a de-identified, aggregated database of real world medication adherence/persistence and clinical outcomes.

The P-MAPP is unique in its randomized design, implementation in multiple pharmacy settings and use of predictive analytics to define drivers of non-adherence behaviours.

P-MAPP’s distinctive platform combines digital technologies, predictive analytics, and provider engagement to create personalized intervention strategies to address, monitor, and modify patients’ behaviors related to medication non-adherence.

The P-MAPP includes many "FIRSTS":​

“The patient is the most underused resource in healthcare.”
Warner Slack MD, Harvard Medical School
Electronic Medical Records Pioneer and Champion of “Patient Power”